Skip Nav Destination
Issues
1 June 2011
-
Cover Image
Cover Image
MCAK is a kinesin-related motor protein that stimulates microtubule depolymerization. It localizes to centrosomes and nuclei during interphase, and to spindle poles and chromosome centromeres during mitosis. The cover figure shows a mixture of non-transfected and FLAGMCAK expressing cells that were stained for DNA (blue), FLAG-MCAK (green), and tubulin (red). MCAK overexpression increased the frequency of microtubule detachment from centrosomes, reduced the amount of microtubule polymer, and caused cells to exit from mitosis without cytokinesis, thereby producing large multinucleated cells with few and fragmented microtubules. The microtubule stabilizing drug paclitaxel was able to counteract the effects of MCAK overproduction. For details, see the article by Ganguly and colleagues on page 929. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Therapeutic Discovery
The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Jenny E. Hernandez-Davies; Joan P. Zape; Elliot M. Landaw; Xiaolin Tan; Ajia Presnell; Diana Griffith; Michael C. Heinrich; Keith B. Glaser; Kathleen M. Sakamoto
A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos
Laura L. Vollmer; Maria Jiménez; Daniel P. Camarco; Wei Zhu; Hikmat N. Daghestani; Raghavan Balachandran; Celeste E. Reese; John S. Lazo; Neil A. Hukriede; Dennis P. Curran; Billy W. Day; Andreas Vogt
Preclinical Development
Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
Joseph M. Gozgit; Matthew J. Wong; Scott Wardwell; Jeffrey W. Tyner; Marc M. Loriaux; Qurish K. Mohemmad; Narayana I. Narasimhan; William C. Shakespeare; Frank Wang; Brian J. Druker; Tim Clackson; Victor M. Rivera
Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma
Ron D. Jachimowicz; Giulio Fracasso; Paul J. Yazaki; Barbara E. Power; Peter Borchmann; Andreas Engert; Hinrich P. Hansen; Katrin S. Reiners; Madlener Marie; Elke Pogge von Strandmann; Achim Rothe
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera; Rachel M. Squillace; David Miller; Lori Berk; Scott D. Wardwell; Yaoyu Ning; Roy Pollock; Narayana I. Narasimhan; John D. Iuliucci; Frank Wang; Tim Clackson
Molecular Medicine in Practice
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Monika E. Hegi; Annie-Claire Diserens; Pierre Bady; Yuta Kamoshima; Mathilde C. M. Kouwenhoven; Mauro Delorenzi; Wanyu L. Lambiv; Marie-France Hamou; Matthias S. Matter; Arend Koch; Frank L. Heppner; Yasuhiro Yonekawa; Adrian Merlo; Karl Frei; Luigi Mariani; Silvia Hofer
Advertisement